Navamedic ASA (NAVA) - Financial and Strategic SWOT Analysis Review
Navamedic ASA (NAVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Navamedic ASA (Navamedic) is a pharmaceutical company developing, producing and marketing medicines and related products. It offers products in branded generics, specialty pharma, medical nutrition and consumer health. In specialty pharma and consumer health, the company focuses on specific categories like women’s health, cardiology, gastro, obesity, cough and cold, dermatology, urology, woundcare and pain relief. Navamedic offers products to patients, hospitals, wholesalers and pharmacy chains in the Nordic, Benelux, Baltic countries and other European nations including UK and Greece. The company distributes more than 40 products supplied by several international pharmaceutical manufacturers through its subsidiary Navamedic AB, in the European market. Navamedic is headquartered in Oslo, Norway.
Navamedic ASA Key Recent Developments
Jun 17,2021: Navamedic announces it has won the tender for certain antibiotics to the Norwegian hospital market
Jun 01,2021: Navamedic: Launch of new products strengthen the category of Medical Nutrition
May 20,2021: Navamedic : Obesity patient support program launched in Norway
May 11,2021: Navamedic: Q1 2021 financial
May 07,2021: Navamedic: Icepharma new distributor of antibiotics to the Icelandic market
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Navamedic ASA (Navamedic) is a pharmaceutical company developing, producing and marketing medicines and related products. It offers products in branded generics, specialty pharma, medical nutrition and consumer health. In specialty pharma and consumer health, the company focuses on specific categories like women’s health, cardiology, gastro, obesity, cough and cold, dermatology, urology, woundcare and pain relief. Navamedic offers products to patients, hospitals, wholesalers and pharmacy chains in the Nordic, Benelux, Baltic countries and other European nations including UK and Greece. The company distributes more than 40 products supplied by several international pharmaceutical manufacturers through its subsidiary Navamedic AB, in the European market. Navamedic is headquartered in Oslo, Norway.
Navamedic ASA Key Recent Developments
Jun 17,2021: Navamedic announces it has won the tender for certain antibiotics to the Norwegian hospital market
Jun 01,2021: Navamedic: Launch of new products strengthen the category of Medical Nutrition
May 20,2021: Navamedic : Obesity patient support program launched in Norway
May 11,2021: Navamedic: Q1 2021 financial
May 07,2021: Navamedic: Icepharma new distributor of antibiotics to the Icelandic market
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Navamedic ASA - Key Facts
Navamedic ASA - Key Employees
Navamedic ASA - Key Employee Biographies
Navamedic ASA - Key Operational Employees
Navamedic ASA - Major Products and Services
Navamedic ASA - History
Navamedic ASA - Company Statement
Navamedic ASA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Navamedic ASA - Business Description
Product Category: Branded generics
Overview
Performance
Product Category: Consumer health
Overview
Performance
Product Category: Medical nutrition
Overview
Performance
Product Category: Others
Performance
Product Category: Specialty pharma
Overview
Performance
Geographical Segment: Denmark
Performance
Geographical Segment: Finland
Performance
Geographical Segment: Norway
Performance
Geographical Segment: Other countries
Performance
Geographical Segment: Sweden
Performance
Navamedic ASA - Corporate Strategy
Navamedic ASA - SWOT Analysis
SWOT Analysis - Overview
Navamedic ASA - Strengths
Navamedic ASA - Weaknesses
Navamedic ASA - Opportunities
Navamedic ASA - Threats
Navamedic ASA - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Navamedic ASA, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Jun 17, 2021: Navamedic announces it has won the tender for certain antibiotics to the Norwegian hospital market
Jun 01, 2021: Navamedic: Launch of new products strengthen the category of Medical Nutrition
May 20, 2021: Navamedic : Obesity patient support program launched in Norway
May 11, 2021: Navamedic: Q1 2021 financial
May 07, 2021: Navamedic: Icepharma new distributor of antibiotics to the Icelandic market
May 06, 2021: Navamedic ASA: Invitation to 2021 first quarter presentation
Apr 30, 2021: Navamedic: Annual report 2020
Apr 08, 2021: Navamedic ASA: Enters long term distribution agreement for PrecisionBiotics Zenflore in the Nordics with Novozymes.
Feb 18, 2021: Navamedic : Q4 2020 financial results
Nov 06, 2020: Navamedic: Q3 2020 financial results
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Navamedic ASA - Key Facts
Navamedic ASA - Key Employees
Navamedic ASA - Key Employee Biographies
Navamedic ASA - Key Operational Employees
Navamedic ASA - Major Products and Services
Navamedic ASA - History
Navamedic ASA - Company Statement
Navamedic ASA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Navamedic ASA - Business Description
Product Category: Branded generics
Overview
Performance
Product Category: Consumer health
Overview
Performance
Product Category: Medical nutrition
Overview
Performance
Product Category: Others
Performance
Product Category: Specialty pharma
Overview
Performance
Geographical Segment: Denmark
Performance
Geographical Segment: Finland
Performance
Geographical Segment: Norway
Performance
Geographical Segment: Other countries
Performance
Geographical Segment: Sweden
Performance
Navamedic ASA - Corporate Strategy
Navamedic ASA - SWOT Analysis
SWOT Analysis - Overview
Navamedic ASA - Strengths
Navamedic ASA - Weaknesses
Navamedic ASA - Opportunities
Navamedic ASA - Threats
Navamedic ASA - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Navamedic ASA, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Jun 17, 2021: Navamedic announces it has won the tender for certain antibiotics to the Norwegian hospital market
Jun 01, 2021: Navamedic: Launch of new products strengthen the category of Medical Nutrition
May 20, 2021: Navamedic : Obesity patient support program launched in Norway
May 11, 2021: Navamedic: Q1 2021 financial
May 07, 2021: Navamedic: Icepharma new distributor of antibiotics to the Icelandic market
May 06, 2021: Navamedic ASA: Invitation to 2021 first quarter presentation
Apr 30, 2021: Navamedic: Annual report 2020
Apr 08, 2021: Navamedic ASA: Enters long term distribution agreement for PrecisionBiotics Zenflore in the Nordics with Novozymes.
Feb 18, 2021: Navamedic : Q4 2020 financial results
Nov 06, 2020: Navamedic: Q3 2020 financial results
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Navamedic ASA, Key Facts
Navamedic ASA, Key Employees
Navamedic ASA, Key Employee Biographies
Navamedic ASA, Key Operational Employees
Navamedic ASA, Major Products and Services
Navamedic ASA, History
Navamedic ASA, Other Locations
Navamedic ASA, Subsidiaries
Navamedic ASA, Key Competitors
Navamedic ASA, Ratios based on current share price
Navamedic ASA, Annual Ratios
Navamedic ASA, Annual Ratios (Cont...1)
Navamedic ASA, Annual Ratios (Cont...2)
Navamedic ASA, Interim Ratios
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Navamedic ASA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Navamedic ASA, Key Facts
Navamedic ASA, Key Employees
Navamedic ASA, Key Employee Biographies
Navamedic ASA, Key Operational Employees
Navamedic ASA, Major Products and Services
Navamedic ASA, History
Navamedic ASA, Other Locations
Navamedic ASA, Subsidiaries
Navamedic ASA, Key Competitors
Navamedic ASA, Ratios based on current share price
Navamedic ASA, Annual Ratios
Navamedic ASA, Annual Ratios (Cont...1)
Navamedic ASA, Annual Ratios (Cont...2)
Navamedic ASA, Interim Ratios
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Navamedic ASA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Navamedic ASA, Performance Chart (2016 - 2020)
Navamedic ASA, Ratio Charts
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Navamedic ASA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Navamedic ASA, Performance Chart (2016 - 2020)
Navamedic ASA, Ratio Charts
Navamedic ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Navamedic ASA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021